GleamWall
中文EN

TRDA Entrada Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1689375 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.5%
TTM net income YoY-56.0%
TTM EPS YoY-49.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,303.8%
Net margin-4,058.0%
FCF margin-3,428.1%
EBITDA margin-4,223.6%

Returns

ROE-59.9%
ROA-47.5%
ROIC (approx.)-82.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets25.7%
Debt / equity0.00x
Current ratio7.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$25.42M$210.78M
R&D expense$142.27M$125.31M
SG&A expense$41.05M$38.47M
Operating income-$157.90M$47.01M
Income tax$924,000$859,000
Net income-$143.75M$65.63M
EBITDA-$153.80M$50.78M
EPS (basic)-3.471.76
EPS (diluted)-3.471.68
Weighted avg. shares (diluted)41.37M39.00M
Balance sheet
Cash & equivalents$90.39M$105.16M
Current assets$306.25M$440.04M
PP&E, net$7.31M$10.93M
Total assets$377.38M$526.32M
Current liabilities$24.45M$39.48M
Total liabilities$71.25M$97.64M
Shareholders' equity$306.13M$428.68M
Shares outstanding38.28M37.57M
Cash flow statement
Operating cash flow-$128.51M-$41.56M
Capital expenditure$1.04M$3.16M
Free cash flow-$129.55M-$44.72M
Investing cash flow$116.81M-$27.80M
Financing cash flow$887,000$102.96M
Depreciation & amortization$4.10M$3.77M
Stock-based compensation$19.61M$17.91M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.